Clinical Cancer Research, Vol 3, Issue 6 983-992, Copyright © 1997 by American Association for Cancer Research

ARTICLES

Elevated stromal chondroitin sulfate glycosaminoglycan predicts progression in early-stage prostate cancer

C Ricciardelli, K Mayne, PJ Sykes, WA Raymond, K McCaul, VR Marshall, WD Tilley, JM Skinner and DJ Horsfall
Departments of Surgery, Flinders University School of Medicine, Bedford Park, South Australia 5042.

Curative therapies for clinically localized prostate cancer have significant morbidity, and those patients who might be cured by aggressive management are not easily identified using current clinical information. Better biomarkers of tumor behavior need to be identified to improve clinical outcome. Chondroitin sulfate (CS), a glycosaminoglycan, may be a potentially useful biomarker as it is known to influence cell growth and differentiation and might influence malignant progression. In this study, CS was immuno-localized to the periacinar and peritumoral fibromuscular stromal tissue of nonmalignant and malignant prostates. The CS concentration was increased in the prostate tissue of men with early-stage prostate cancer compared with tissue from men without cancer (P < 0.0001). Using Cox's univariate analysis, CS concentration, tumor grade, preoperative serum prostate-specific antigen (PSA), extracapsular extension of disease, positive surgical margins, and patient age were associated with an increased risk of PSA failure. The CS concentration was compared with the other features in two-variable regression analyses. CS and preoperative serum PSA concentrations were independent predictors of PSA failure. CS was a stronger prognostic feature than tumor grade and could predict outcome for patients with moderately differentiated tumors. Patients with a low CS concentration had significantly better progression-free survival following radical prostatectomy than patients with high levels of CS (Kaplan-Meier plot, 91% versus 49% PSA progression free at 5 years, respectively, P = 0.0038). Only postoperative pathological indices (extracapsular extension, surgical margins) were stronger predictors than CS. We conclude that measurement of prostatic CS concentrations at diagnosis may allow stratification of patients with early-stage prostate cancer for adjunctive or alternate therapies.

This article has been cited by other articles:

				C. Ricciardelli, D. L. Russell, M. P. Ween, K. Mayne, S. Suwiwat, S. Byers, V. R. Marshall, W. D. Tilley, and D. J. Horsfall Formation of Hyaluronan- and Versican-rich Pericellular Matrix by Prostate Cancer Cells Promotes Cell Motility J. Biol. Chem., April 6, 2007; 282(14): 10814 - 10825. [Abstract] [Full Text] [PDF]

				S. Suwiwat, C. Ricciardelli, R. Tammi, M. Tammi, P. Auvinen, V.-M. Kosma, R. G. LeBaron, W. A. Raymond, W. D. Tilley, and D. J. Horsfall Expression of Extracellular Matrix Components Versican, Chondroitin Sulfate, Tenascin, and Hyaluronan, and Their Association with Disease Outcome in Node-Negative Breast Cancer Clin. Cancer Res., April 1, 2004; 10(7): 2491 - 2498. [Abstract] [Full Text] [PDF]

				H. Yoon, S. Liyanarachchi, F. A. Wright, R. Davuluri, J. C. Lockman, A. de la Chapelle, and N. S. Pellegata Gene expression profiling of isogenic cells with different TP53 gene dosage reveals numerous genes that are affected by TP53 dosage and identifies CSPG2 as a direct target of p53 PNAS, November 26, 2002; 99(24): 15632 - 15637. [Abstract] [Full Text] [PDF]

				C. Ricciardelli, D. I. Quinn, W. A. Raymond, K. McCaul, P. D. Sutherland, P. D. Stricker, J. J. Grygiel, R. L. Sutherland, V. R. Marshall, W. D. Tilley, et al. Elevated Levels of Peritumoral Chondroitin Sulfate Are Predictive of Poor Prognosis in Patients Treated by Radical Prostatectomy for Early-Stage Prostate Cancer Cancer Res., May 1, 1999; 59(10): 2324 - 2328. [Abstract] [Full Text] [PDF]